pharma news today glp-1 obesity drug What is the pipeline for future medications for obesity? GLP-1 Drugs from the Gray

Apply at night for maximum AHA exfoliation without UV sensitivity concerns

Bivamelagon Bivamelagon (formerly LB54640) is an oral MC4R-selective small molecule agonist as shown in Figure 2 , with nanomolar potency on hMC1R (EC 50 = 84.82 nM) and hMC3R (EC 50 = 130 nM) and low nanomolar potency on hMC4R (EC 50 = 0.98-16.28 nM) ( Table 1 ) (98)

These medications are increasingly being prescribed to women struggling with PCOS, insulin resistance, and metabolic-related infertility

However, the technology requires specialized equipment and training that limit widespread implementation (Alcazar et al., 2011)

83 TurgemanA.McRaeH

In October, a compounding industry group, the Outsourcing Facility Association, filed a lawsuit against the FDA's decision that there was no longer a shortage of tirzepatide, the active ingredient fin Zepbound and Mounjaro